Table 1.
Patient baseline characteristics and RNA Integrity Numbers (RIN) of myocardial left ventricular RNA samples according to subgroups
| Control (n = 9) | HCM (n = 7) | DCM (n = 12) | IHD (n = 14) | IHD-T2DM (n = 11) | CRT:DCM (n = 9) | CRT:IHD (n = 9) | CRT:IHD-T2DM (n = 9) | |
|---|---|---|---|---|---|---|---|---|
| Age (years) | 68.6 ± 1.9 | 36.6 ± 4.4 | 46.8 ± 3.4 | 58.7 ± 1.4 | 57.0 ± 1.4 | 47.7 ± 4.1 | 59.0 ± 1.6 | 60.1 ± 1.6 |
| Sex (F, %) | 8/9 (89%) | 4/7 (57%) | 2/12 (17%) | 5/12 (36%) | 3/11 (27%) | 3/9 (33%) | 0/9 (0%) | 2/9 (22%) |
| BMI (kg/m2) | 26.1 ± 1.6 | 25.5 ± 1.9 | 25.7 ± 1.6 | 26.5 ± 0.8 | 27.9 ± 0.9 | 23.5 ± 1.0 | 27.7 ± 1.6 | 30.0 ± 1.1 |
| LVEDD (mm) | 53.2 ± 4.0 | 50.7 ± 4.6 | 73.4 ± 2.6 | 69.9 ± 2.7 | 63.9 ± 2.7 | 76.2 ± 3.8 | 70.6 ± 6.2 | 70.0 ± 3.6 |
| EF (%) | 61.2 ± 3.4 | 36.9 ± 4.6 | 21.9 ± 1.1 | 27.3 ± 1.4 | 22.9 ± 1.9 | 19.3 ± 2.7 | 19.7 ± 2.4 | 23.3 ± 2.4 |
| FS (%) | 32.1 ± 3.8 | 20.7 ± 3.5 | 10.9 ± 0.9 | 14.6 ± 1.6 | 13.0 ± 2.5 | 8.2 ± 2.5 | 14.7 ± 3.7 | 15.5 ± 1.4 |
| Years with CRT | – | – | – | – | – | 2.9 ± 0.6 | 3.2 ± 1.8 | 3.4 ± 0.8 |
| BB | 8/9 (89%) | 5/7 (71%) | 9/12 (75%) | 11/14 (79%) | 4/11 (36%) | 2/9 (22%) | 8/9 (89%) | 8/9 (89%) |
| ACEi or ARB | 1/9 (11%) | 0/7 (0%) | 7/12 (58%) | 11/14 (79%) | 9/11 (82%) | 3/9 (33%) | 7/9 (78%) | 8/9 (89%) |
| MRA | 2/9 (22%) | 4/7 (57%) | 9/12 (75%) | 13/14 (89%) | 8/11 (73%) | 6/9 (67%) | 8/9 (89%) | 6/9 (67%) |
| Diuretic | 4/9 (44%) | 4/7 (57%) | 10/12 (83%) | 11/14 (79%) | 7/11 (64%) | 7/9 (78%) | 7/9 (78%) | 6/9 (67%) |
| Statin | 3/9 (33%) | 0/7 (0%) | 2/12 (17%) | 7/14 (50%) | 6/11 (55%) | 0/9 (0%) | 4/9 (44%) | 8/9 (89%) |
| SU | – | – | – | – | 2/11 (18%) | – | – | 2/9 (22%) |
| Metformin | – | – | – | – | 6/11 (55%) | – | – | 5/9 (55%) |
| DPP4i | – | – | – | – | 4/11 (36%) | – | – | 1/9 (11%) |
| Insulin | – | – | – | – | 3/11 (27%) | – | – | 1/9 (11%) |
| RIN | 9.3 ± 0.1 | 8.3 ± 0.4 | 8.4 ± 0.3 | 8.1 ± 0.4 | 8.2 ± 0.3 | 7.9 ± 0.3 | 8.0 ± 0.3 | 7.9 ± 0.3 |
HCM hypertrophic cardiomyopathy, DCM dilated cardiomyopathy, IHD ischemic heart disease, T2DM type 2 diabetes mellitus, CRT cardiac resynchronization therapy, BMI body mass index, LVEDD left ventricular end-diastolic diameter, EF left ventricular ejection fraction, FS fractional shortening, BB beta blocker, ACEi angiotensin converting enzyme inhibitor, ARB angiotensin II receptor blocker, MRA mineralocorticoid receptor antagonist, SU sulfonylurea, DPP4i dipeptidyl peptidase-4 inhibitor, RIN RNA integrity number